US20100248237A1 - Miniaturized, high-throughput nucleic acid analysis - Google Patents

Miniaturized, high-throughput nucleic acid analysis Download PDF

Info

Publication number
US20100248237A1
US20100248237A1 US12/709,782 US70978210A US2010248237A1 US 20100248237 A1 US20100248237 A1 US 20100248237A1 US 70978210 A US70978210 A US 70978210A US 2010248237 A1 US2010248237 A1 US 2010248237A1
Authority
US
United States
Prior art keywords
beads
primer
nucleic acid
bead
pcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/709,782
Other languages
English (en)
Inventor
Thomas Froehlich
Dieter Heindl
Angelika Roesler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Molecular Systems Inc
Original Assignee
Roche Diagnostics Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Operations Inc filed Critical Roche Diagnostics Operations Inc
Assigned to ROCHE DIAGNOSTICS GMBH reassignment ROCHE DIAGNOSTICS GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HEINDL, DIETER, FROEHLICH, THOMAS, ROESLER, ANGELIKA
Assigned to ROCHE DIAGNOSTICS OPERATIONS, INC. reassignment ROCHE DIAGNOSTICS OPERATIONS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ROCHE DIAGNOSTICS GMBH
Publication of US20100248237A1 publication Critical patent/US20100248237A1/en
Priority to US13/746,812 priority Critical patent/US8822158B2/en
Assigned to ROCHE MOLECULAR SYSTEMS, INC. reassignment ROCHE MOLECULAR SYSTEMS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ROCHE DIAGNOSTICS OPERATIONS, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6846—Common amplification features

Definitions

  • This invention relates to the area of nucleic acid analysis and in particular to the miniaturized, highly parallel detection of nucleic acid sequences and analysis of differences in nucleic acid sequences.
  • the invention is based on the idea of providing a solid support to which sequence specific primers are bound, with one being cleavable and the other being non-cleavable, in order to analyze specific sequences or detect the presence of a SNP, a mutation or any particular DNA or RNA species of interest.
  • a primer extension reaction is performed, where the 4 different A, G, C, and T nucleoside triphosphates or their respective analogs are supplied in a repetitive series of events and the sequence of the nascent strand is inferred from chemical products derived from the extension reaction catalyzed by the DNA polymerase.
  • the sequencing by synthesis reaction is a pyrophosphate sequencing reaction, characterized in that generation of pyrophosphate is detected as follows:
  • WO 04/69849 discloses a method of amplifying a plurality of nucleic acids (e.g., each sequence of a DNA library, transcriptome, or genome) in a rapid and economical manner in a single reaction tube. More particularly. WO 04/69849 discloses a simultaneous clonal amplification (e.g., by PCR) of a plurality of samples (as many as several hundred thousand) in one reaction vessel.
  • a simultaneous clonal amplification e.g., by PCR
  • WO 04/69849 provides a means for encapsulating a plurality of DNA samples individually in a microcapsule of an emulsion (i.e., a microreactor), performing amplification of the plurality of encapsulated nucleic acid samples simultaneously, and releasing said amplified plurality of DNA from the microcapsules for subsequent reactions.
  • a microcapsule of an emulsion i.e., a microreactor
  • single copies of the nucleic acid template species are hybridized to capture beads comprising, e.g., capture oligonucleotides or chemical groups that bind to the nucleic acid template.
  • the beads are suspended in complete amplification solution and emulsified to produce microreactors (typically 100 to 200 microns in diameter).
  • amplification e.g., PCR
  • capture beads are added to an amplification reaction mixture comprising nucleic acid template and this mixture is emulsified to produce microreactors.
  • Amplification e.g., PCR
  • Amplification is used to clonally increase copy number of the initial template species in the microreactors, and these copies bind to the capture beads in the microreactors.
  • microreactors according to WO 05/03375 allow the simultaneous clonal and discrete amplification of many different templates without cross contamination of the amplified products or reagents, or domination of one particular template or set of templates (e.g., PCR bias).
  • PCR polymerase chain reaction
  • WO 2001/062982 and U.S. Pat. No. 5,641,658 describe PCR on bead surfaces with two immobilized primers.
  • the PCR method is named bridge amplification.
  • WO 2001/012862 describes a method for generating a pool of oligonucleotides by cleaving different oligonucleotides which are attached to a substrate via different cleavable linkers.
  • WO 2007/111937 describes an array for primer pairs where at least one primer is attached via a cleavable linkage for enrichment of genomic DNA used in sequencing.
  • KR 2007044677 describes beads with a first and a second immobilized PCR primer for use in emulsion PCR.
  • the first primer is non cleavable.
  • the release of the second primer is achieved by changing the pH value. Yet, changing the pH value has the disadvantage of potentially undesired side reactions and furthermore makes further processing of the sample more difficult.
  • the present invention is directed to a method for treating multiple nucleic acid molecules of interest comprising in the steps of:
  • step c) comprises the generation of an emulsion wherein each bead is encapsulated in a single micelle.
  • step f) comprises the distribution of said plurality of beads into the cavities of a micro- or picotiter plate and detecting said amplification products.
  • step f) further comprises a sequencing reaction of said amplification products.
  • said sequencing reaction is a sequencing by synthesis reaction, for example a pyrosequencing reaction.
  • a method may be used for quantitative mutational analysis.
  • the plurality of molecules corresponds to a plurality of different cellular RNAs or their corresponding cDNAs, such a method may be used for monitoring gene expression.
  • the generation of said amplification products for example by means of PCR is monitored.
  • said amplification products are detected by means of a specifically double-stranded DNA binding fluorescent entity, a sequence specific hybridization probe:
  • said amplification products may be analyzed by means of subjecting said amplification products to a thermal gradient.
  • step c) comprises the distribution of said plurality of beads into the cavities of a micro- or picotiter plate.
  • steps e) and f) are performed simultaneously by means of Real Time PCR. Subsequent to PCR, a melting curve analysis may be performed.
  • At least one primer which is bound to the bead via a cleavable linker carries a detectable tag.
  • said detectable tag is selected from a group consisting of mass-tag, color label, e-tag and a hapten which is detectable by an antibody. Highly preferred is a fluorescent label which is preferably quenched as long as said labeled primer has not been elongated.
  • the cleavable primer carries a detectable tag. In this case, said amplification products are detected using labeled primers or labeled dNTPs.
  • the detectable tag may be a hapten such as Biotin or Digoxygenin.
  • each member of the plurality of primers which are bound to the bead via a cleavable linker carries a different detectable label.
  • PCR is performed within the scope of the present invention and the plurality of nucleic acids comprises either standard nucleic acids or internal reference nucleic acids
  • the present invention is also applicable for absolute nucleic acid quantification.
  • PCR is performed within the scope of the present invention on a plurality of different nucleic acid molecules which are either cellular RNAs or their corresponding cDNAs, the present invention may be used for monitoring gene expression.
  • the inventive method is applicable for performing a quantitative mutational analysis.
  • orthogonal protecting groups can be selectively removed dependent on the conditions applied.
  • FIG. 1 illustrates the assay principle based on primers that are specific for the target nucleic acid and immobilized on a coded solid carrier (e.g., bead).
  • the stationary primer 1 is used for target capturing, whilst primer 2 will be photolytically cleaved off the carrier to drive clonal PCR amplification of the captured target in emulsion.
  • NHS N-hydroxysuccinimide ester
  • FIG. 3A-B Absorbance measurement in FIG. 3A demonstrates the solubilization of a fluorescein-modified oligonucleotide probe (Sequence ID #1) when photolytically cleaved off sepharose beads.
  • the flow cytometric measurement in FIG. 3B shows photocleavage indicated by decrease in fluorescence intensity when sepharose beads conjugated with fluorescein-modified oligonucleotide probes (Sequence ID #1) are subjected to a photocleavage reaction in suspension or emulsion.
  • FIG. 4 illustrates the restriction endonuclease assay detecting conventional PCR products and PCR products immobilized to beads carrying stationary and photo-cleavable primer (Sequence ID # 2, 3).
  • FIG. 5 shows the gel electrophoretic detection and identification of double stranded DNA obtained after conventional PCR or after PCR using bead immobilized primer (Sequence ID #2, 3) in suspension.
  • FIG. 6 shows the gel electrophoretic detection and identification of double stranded DNA obtained after conventional PCR or after PCR using bead immobilized primer (Sequence ID #2, 3) in emulsion.
  • FIG. 7 demonstrates via restriction endonuclease treatment and gel electrophoresis that specific PCR products can be obtained with emulsion PCR and bead immobilized primer (Sequence ID #4, 5) using HeLa cDNA or an amplicon as template.
  • FIG. 8 illustrates the restriction endonuclease assay detecting PCR products immobilized to a set of distinct beads carrying stationary and photo-cleavable primer (Sequence ID #4-9) after multiplexed PCR.
  • FIG. 9A-B Electropherograms in FIGS. 9 A and B show the detection and identification of double stranded DNA obtained after multiplexed PCR using a set of distinct bead immobilized primer (Sequence ID #4-9) in suspension and in emulsion.
  • the present invention is directed to a solid support comprising at least two sequence specific amplification primers wherein at least one primer is bound to said support with an inducible cleavable linker.
  • a bead according to the present invention is especially useful for a method of analyzing a nucleic acid by means of contacting said nucleic acid with multiple beads comprising a pair of capture primers and subsequent amplification.
  • a method according to the present invention comprises the following three phases:
  • the present invention provides a possibility for highly parallel and miniaturized analysis of nucleic acids and includes applications such as qualitative and/or quantitative detection of genes of interest, gene expression analysis, and mutation detection, but is not limited to this.
  • Multiple nucleic acid molecules is understood as a population of molecules characterized in which at least two different nucleic acid sequences are represented. In most cases, a plurality of many different sequences is represented.
  • “Plurality of beads” is understood as a number of more than 1000, preferably more than 10,000, and most preferably more than 100,000 beads
  • Pair of sequence specific amplification primers is understood as two oligonucleotide molecules which together can act as a pair of amplification primers in such a way that during a nucleic acid amplification reaction, an amplification product with a defined length is generated.
  • “Cleavable linker” is understood as a chemical entity comprising a chemical bonding which upon a specific treatment can be resolved in such a way that the remaining parts of the molecule stay intact.
  • the cleavable linker is an “inducible cleavable linker”, which is defined as a cleavable linker which can be resolved by means of providing an external stimulus.
  • an inducible cleavable linker is a photo-cleavable linker, wherein the bonding is resolved by means of treatment with light of a defined wavelength.
  • Capturing is understood as (i) hybridizing a population of nucleic acid molecules with a specific nucleic acid sequence that is immobilized on a solid support such as a bead and which is at least partially complementary to a sequence of interest that may be represented within said population of nucleic acid molecules, and (ii) removal of unhybridized nucleic acid molecules from the formed hybridization complexes.
  • “Clonally isolating” is understood as separating a plurality of beads from each other such that each single bead is placed at a different location.
  • a location is a micro-orpicowell.
  • “Clonally amplifying” is understood that a population of nucleic acid molecules is being amplified in such a way that amplification products originating from different original target molecules are physically separated from each other. For example, all amplification products originating from the same original target nucleic acid molecule may be immobilized on a bead which is enclosed in a micelle.
  • Emmulsion in the context of a present invention is understood as a water-in-oil emulsion, characterized in that small hydrophilic drops comprising a single bead are encapsulated in a micelle which is surrounded by a lipohilic liquid.
  • “Sequencing by synthesis” is understood as determining whether during a primer extension reaction, a specific nucleoside triphosphate has been incorporated which by itself can be elongated during the subsequent step of the primer extension reaction.
  • Subjecting to a thermal gradient is understood as heating or cooling a sample of interest starting from a first defined temperature and ending at a second defined temperature.
  • the gradient may be either a continuous gradient which is preferably linear or alternatively a step-gradient. If PCR products or hybrids of nucleic acid probes and target molecules are subjected to such a gradient, a melting curve analysis or a monitoring of temperature dependence of hybridization can be performed.
  • Real time PCR is understood as a polymerase chain reaction characterized in that the progress of the amplification reaction is monitored at least once within one amplification cycle.
  • amplification is monitored with either an intercalating fluorescent dye or, alternatively, with amplicon specific nucleic acid hybridization probe such as, for example, a 5′ nuclease TaqMan probe, a molecular beacon probe, or a pair of FRET hybridization probes.
  • “Quenching” is understood as decreasing the emission of fluorescence from a fluorescent compound which is caused by a second chemical entity which is in close spatial vicinity to said fluorescent compound.
  • “Quantitative mutational analysis” is understood as a method comprising the steps of (i) screening of a plurality of nucleic acid molecules with essentially identical sequences for sequence variations, and (ii) determining the rate or the rates at which at least one or several of such sequence variations are present within said plurality of nucleic acid molecules.
  • sequence variations may be single nucleotide polymorphism.
  • the present invention requires the reversible covalent attachment of a first sequence specific amplification primer to a solid support via a flexible and cleavable linker molecule such that the primer can hybridized to a target molecule and released into solution for target amplification and detection while a second sequence specific amplification primer stays covalently attached to the surface under cleavage conditions.
  • the cleavable linker molecule can be cleavable by acid, base, light or any other means well known to those trained in the field. Preferably, it is exactly one primer which is bound to the bead via a cleavable linker.
  • the beads have an average size of about 10 ⁇ M to about 250 ⁇ m.
  • the beads Preferably, the beads have an average diameter of about 20 to about 100 ⁇ m.
  • the beads have an average diameter of about 30 ⁇ m to 80 ⁇ m.
  • the beads may have an average diameter of about 40 ⁇ m.
  • the material of the beads to which the two primers shall be attached must be stable against oxidation and to hydrolysis, and may be inorganic, e.g., silicon or titanium dioxide or aluminum oxide or glass; or organic, e.g., polystyrene, cellulose, polyamide and others.
  • a bead is either of one pure material or composed of two or more materials, whereas the two ore more materials are mixed or assembled in a ordered manner like in core shell particles.
  • the surface of the beads may be porous or plain.
  • the surface of a bead is functionalized in such manner that oligonucleotides can be attached. Therefore the surface of the beads has a functionalized surface comprising functional groups like, amino, thiol, carboxyl, maleinimido, azido, alkin, hydrazine, hydroxylamino, keto and aldehyde groups, triazinchloride, quinones, diene, or other reactive functions known by those trained in the field.
  • the corresponding modification of the oligonucleotide is determined by the surface functional group as can be seen in the following table:
  • the functional group is either introduced on the surface, e.g., by silanization of glass-silicacte lanthanide-oxides with an modified silane or the bead by itself contains a priori functional groups which are created during production of the bead, e.g., by copolymerizatin of polystyrene and an appropriate alkene containing the functional group.
  • a priori present functional groups could be transformed in another functional group by using heterobifunctional linkers. Such linker could be cleavable or noncleavable. By this procedure beads with different orthogonal functionalities can be created.
  • Orthogonal means that a first functional group reacts with a first modified oligonucleotide in the presence of a second functional group which reacts simultaneously with the second modified oligonucleotide.
  • a pair of such functional groups is succinylamidocarboxy and alkin, which requires an amino and azido modified oligonucleotide.
  • the bead is a gold particle or the bead is coated with a metal film, e.g., with gold thiol modified oligonucleotides are directly reacted with the surface.
  • Primer oligonucleotides are first synthesized by standard Phosphoramidate chemistry. Such a synthesized primer can be further modified with a cleavable linker molecule either during or subsequent to the oligonucleotide synthesis. Attachment of a cleavable primer and a non-cleavable primer can be achieved by any means of multiple well known attachment chemistries described in the literature for microarray technologies or any other known method. Examples are disclosed and reviewed in Wittebolle, Lieven; Verstuyft, Karmen; Verstraete, Willy; Boon, Nico.
  • the solid support and preferably the bead which according to the present invention comprises at least two sequence specific primers, wherein at least one of said primers is cleavable, is prepared in a new unpredicted manner of combining different steps of solid phase chemistry and oligonucleotide synthesis which as single steps per se are already known in the art.
  • the solid support according to the present invention is prepared by a method comprising the steps of
  • the method according to the present invention comprises the steps of
  • linkers can be used to prepare beads according to the invention.
  • Amino-modified linkers biotin-modified linkers which can be used to attach amino groups or biotin to a terminus of an oligonucleotide, and internal photocleavable linkers which can be used in combination with any other modifier.
  • Cleavable linkers are well known in the art and can be discriminated into two classes.
  • the first class requires a reactive species, e.g., a reductive species or OH ⁇ or H+ in order to achieve cleavage. Examples are disulfide bridges which could be cleaved by reduction with thiols or baselabile “linkers” like an RNA monomer incorporated at the terminus of an oligonucleotide.
  • the second class is cleaved by physical means, e.g., by irradiation such as illumination or heating.
  • Photocleavable linkers are linkers wherein a covalent bond is broken by means of irradiation with light.
  • the irradiation wavelength has to be chosen in such a manner that the nucleobases of the attached oligonucleotidides do not absorb in order to avoid side reactions like T-T dimerization or photoxidation.
  • organic dyes are attached to the bead, e.g., within a detection probe the irridation wavelength does not match absorption of such dyes.
  • photocleavable linkers are for example derived from orthonitrobenzylalkohols, and are well known in the literature.
  • the photocleavage is achieved by irradiation with UV light of the wavelength >340 nm.
  • Photocleavable linkers which can be introduced during oligonucleotide synthesis are exemplarily described in the following references: WO 92/002528, WO 07/082,713, U.S. Pat. No. 5,258,506, Olejnik, Jerzy; Krzymanska-Olejnik, Edyta; Rothschild, Kenneth, J., Nucleic Acids Research 26(15) (1998) 3572-3576, Hausch, F., Jäschke, A., Nucleic Acids Research 28 (2000) e35, Hausch, F., Jäschke, A., Tetrahedron 57 (2001) 1261-1268, Wenzel, T., Elssner, T., Fahr, K., Bimmler, J., Richter, S., Thomas, I., Kostrzewa, M., Nucleosides, Nucleotides & Nucleic Acids 22 (2003) 1579-1581, Dell'Aquila, Christelle; Im
  • a particular mode of indirect photocleavage can be achieved by photogenerating of reactive species like H+ or OH ⁇ whereas the formation of such reactive species results in cleavage of a base or acid labile covalent bond.
  • WO 2006/117556 and WO 99/41007 describe methods for photogeneration of acids and bases.
  • Base or acid labile linkers are well known in the art (e.g., Chitkul, B.; Atrash, B.; Bradley, M., Tetrahedron Letters 42(35) (2001) 6211-6214).
  • a thermally-cleavable linker is described in Keller, Keith, A.; Guo, Jianhua; Purina, Sreenivas; Finn, M., G., Tetrahedron Letters 46(7) (2005) 1181-1184.
  • Immobilized Oligonucleotides are in either case attached to the surface in such a manner that initial target capturing is facilitated and that the PCR is still efficient even with one immobilized primer. This is achieved by allowing sufficient spacing between the bead surface and the primer sequence. Therefore long linkers like PEG-linkers or multiple short linkers are attached to the oligonucleotides.
  • a second parameter influencing capturing is the surface loading density on the bead, which could be controlled by an appropriate bead production process or by diluting the oligonucleotides to be immobilized with non nucleotidic compounds having the same functional group as the oligonucleotide to be immobilized.
  • the solid support to the present invention may be a bead or a plurality of beads.
  • Beads according to present invention may be used within a method for analyzing multiple nucleic acid molecules of interest comprising in the following steps
  • FIG. 1 An exemplary overview is shown in FIG. 1 : A sample is subjected to a population of beads comprising a pair of amplification primers, one of which is photo-cleavable (steps a, b). Clonal amplification is achieved by means of performing an emulsion PCR (steps c, d, e). Subsequently, the amplification products are becoming analyzed (step f).
  • Target molecules are then hybridized to the beads containing the cleavable and non-cleavable primer.
  • Suitable hybridization conditions with respect to the appropriate buffer system and appropriate hybridization temperatures are well known in the art and can be optimized according to the specific conditions such as the lengths and sequences of the specially used amplification primers.
  • Preferably hybridization is done using a molar excess of beads compared to the sequence or sequences which shall be amplified in order to capture as many target nucleic acids as possible.
  • a molar excess of 1:5-1:100 and preferably 1:10-1:50 has been proven to be particular advantageous. If multiple different target sequences shall be detected and/or analyzed, then a library of beads with accordingly different multiple primer pairs has to be used.
  • Clonal isolation is a prerequesite in order to obtain quantitative data with respect to sequence variations that are present in the plurality of nucleic acid molecules which are being analyzed. In principle, there are two different modes of clonal isolation.
  • PCR reagents such as the themostable DNA polymerase, the deoxynucleoside triphosphates and an appropriate buffer are first added to the beads. Subsequently, a water-in-oil emulsion is generated characterized in that each bead is encapsulated in a single micelle containing an aqueous solution which allows for a nucleic acid amplification reaction. Appropriate conditions are for example disclosed in WO 04/069849.
  • about 3000 beads are contained within 1 microliter of a 1:2 water to oil emulsion.
  • step c) comprises the distribution of said plurality of beads into the cavities of a micro- or picotiter plate.
  • the size of the cavities corresponds to the diameter of the beads in such way that one cavity can only be filled with one bead.
  • Distribution of the beads into the cavities can be obtained for example by means of constant agitation, smooth shaking or means of centrifugation.
  • the PCR reagents such as the themostable DNA polymerase, the deoxynucleoside triphosphates and an appropriate buffer are added either prior or preferably subsequently to the distribution of the beads into the cavities of the micro- or picotiter plate. Alternatively addition of said PCR reagents can be performed after step d).
  • the beads comprising said primer which is bound via a cleavable linker are then exposed to cleavage conditions in order to cut the linker attaching the cleavable primer to the bead.
  • the cleavable linker molecule can be cleavable by acid, base, light or any other means well known to those trained in the field.
  • the linker is a photo-cleavable linker because addition of an additional reagent is avoided.
  • the reaction mixtures are then exposed to an appropriate thermocycling protocol in order to perform a nucleic acid amplification reaction.
  • the still immobilized (non-cleavable) amplification primer hybridizes to the target nucleic acid molecule as well as to the amplified products thereby holding them at the surface of the bead.
  • the amplification primer which has been cleaved off the bead is capable of moving free in solution, such that an effective amplification reaction can be performed.
  • the present invention also provides for a method for producing a plurality of nucleic acid template-carrying beads wherein each bead comprises up to and more than 1,000,000 copies of a single nucleic acid sequence. Under optimized conditions, each bead may comprise over 20 million copies of a single nucleic acid.
  • EP 0 799 888 discloses an addition of 3′ blocked oligonucleotides to PCR reactions. Due to the 3′ block, these oligonucleotides can not act as primers. The blocked oligonucleotides are designed to compete/interact with the PCR primers which results in reduction of non-specific products. Another alternative is the use of phosphorothioate oligonucleotide primers in combination with an exonuclease III in the PCR reaction mixes (EP 0 744 470).
  • compositions for performing a nucleic acid amplification reaction comprising (i) a thermostable DNA-Polymerase, (ii) a thermostable 3′-5′ Exonuclease, and (iii) at least one primer for nucleic acid amplification with a modified 3′ terminal residue which is not elongated by said thermostable DNA-Polymerase as well as methods for performing a PCR reaction using this composition.
  • the clonal amplification may be performed in the in the form of an allele specific PCR.
  • variant-specific amplification primers are used during the amplification which usually have a discriminating terminal nucleotide residue at the 3′ terminal end of the primer which is only complementary to a special variant of the target nucleic acid to be detected.
  • U.S. Pat. No. 5,595,890 for example describes such methods for allele-specific amplification and their use to detect clinically relevant point mutations for example in the k-ras oncogene.
  • U.S. Pat. No. 5,521,301 also describes methods for allele-specific amplification for genotyping the AB0 blood group system. In contrast U.S. Pat. No.
  • 5,639,611 discloses the use of allele-specific amplification in connection with the detection of the point mutation responsible for sickle cell anaemia.
  • Such methods for detecting sequence variants, polymorphisms and, above all, point mutations require an allele-specific amplification particularly when the sequence variant to be detected is present in a lower amount compared to a variant of the same section of nucleic acid (or of the same gene) that is present in excess. This situation for example occurs when the aim is to detect disseminating tumour cells in body fluids such as blood, serum or plasma with the aid of allele-specific amplification (U.S. Pat. No. 5,496,699).
  • the DNA is firstly isolated from body fluids such as blood, serum or plasma which is composed of a relatively small amount of DNA from disseminating tumour cells and an excess of DNA from non-proliferating cells.
  • body fluids such as blood, serum or plasma
  • mutations in the k-Ras gene that are significant for tumoral DNA have to be detected on the basis of a few copies of tumoral DNA in the presence of an excess of wild type DNA.
  • step c) In case clonal isolation of step c) has been achieved by means of generating a water-in-oil emulsion, it is required that in a first step, the plurality of beads carrying the amplification products is distributed into the cavities of a micro- or picotiter plate Subsequently there exist two alternative embodiments for analysis of the generated amplification products.
  • the DNA bound to each bead may be subjected to a sequencing reaction.
  • said sequencing reaction is a sequencing by synthesis reaction, characterized in that incorporation of specific deoxynucleoside into the nascent DNA strand of a primer extension reaction is being monitored.
  • said sequencing by synthesis reaction is a pyrophosphate sequencing reaction, wherein said incorporation is being monitored by means of detecting the generation of pyrophosphate (EP 932 700, U.S. Pat. No. 6,210,891).
  • the emPCR itself is performed with multiple beads, but all beads are carrying the same pair of amplification primers. More precisely, the beads have one immobilized forward and backward primer, both specific for the same gene.
  • the non-cleavable primer may have an additional sequence at the 5′-end followed by a gene specific priming sequence.
  • the cleavable primer has a specific sequence at the 5′-end, which prior to the sequencing reaction may act as a sequencing primer binding site. The 3′ part of said cleavable primer is followed by a gene specific sequence. It is less preferred but still within the scope of the present invention, if the sequence corresponding to the sequencing primer binding site is present at the 5′ end of non-cleavable primer.
  • each containing primer pairs for different genes can be pooled.
  • the target is then hybridized onto the beads in a capturing reaction.
  • an emulsion suited for emPCR is generated.
  • the emulsion then is submitted to conditions that cleave the cleavable linker.
  • the beads then are subjected to “clonal amplification” by emPCR. After breaking of the emulsion and washing, the beads are physically separated on a picotiter plate and the amplification product is decoded/detected and/or quantified by sequencing, for example with the Genome Sequencer FLX instrument (Roche Applied Science Cat. No. 04 896 548 001).
  • the main advantages are that the target can be directly added to the beads and no pre-amplification of the genes or amplicons of interest is needed.
  • sequence specific capture beads There is a possibility to supply a pool of sequence specific capture beads.
  • the pools of sequence specific capture beads may be grouped into specific applications such as gene expression of oncology relevant genes and others.
  • the amplified DNA which is still bound to the bead may be analyzed directly by appropriate detection means.
  • a PCR assay is performed characterized in that the generation of the amplicon is subject to an end-point measurement.
  • the beads have an immobilized forward and backward primer, both specific for one gene or nucleic acid sequence region of interest.
  • One of the primers is cleavable, and the second primer is non-cleavable.
  • Many different beads, each containing primer pairs for different genes/sequences are pooled.
  • the target nucleic acid sample is hybridized onto the beads in a capturing reaction.
  • An Emulsion suited for emPCR is generated.
  • the emulsion is then submitted to conditions that cleave the cleavable linker. Subsequently, the beads are subjected to “clonal amplification” by emPCR.
  • the beads After breaking of the emulsion and washing the beads are physically separated on a PTP (picotiter plate) and the amplification product is detected in an end-point assay.
  • said detection is performed by means of subjecting the generated amplicons to a thermal gradient.
  • a melting curve analysis U.S. Pat. No. 6,174,670, U.S. Pat. No. 5,871,908.
  • the amplification products are preferably detected by means of fluorescence.
  • the amplification mix may already contain a double stranded nucleic acid binding moiety such as a fluorescent DNA binding dye which emits a corresponding fluorescence signal upon interaction with the double-stranded nucleic acid after excitation with light of a suitable wavelength.
  • a fluorescent DNA binding dye which emits a corresponding fluorescence signal upon interaction with the double-stranded nucleic acid after excitation with light of a suitable wavelength.
  • the dyes SybrGreenI and SybrGold (Molecular Probes) or dyes as disclosed in WO 2004/038038 have proven to be particularly suitable for this application. Other intercalating dyes can alternatively be used
  • amplicon detection with SybrGreen format can not discriminate between specific products and amplification artefacts such as primer/dimers
  • a subsequent melting curve analysis is usually performed. After completion of the PCR-reaction, the temperature of the sample is constitutively increased, and fluorescence is detected as long as SybrGreen is bound to the double stranded DNA present in the samples. Upon dissociation of the double stranded DNA the signal decreases immediately. This decrease is monitored with an appropriate fluorescence versus temperature-time plot such that a first derivative value can be determined, at which the maximum of fluorescence decrease is observed. Since primer/dimer double stranded DNAs are usually short, dissociation into single stranded DNA occurs at lower temperatures as compared to the dissociation of the double stranded specific amplification product.
  • the amplification mix may contain already one or more hybridization probes which are labeled with at least one fluorescent moiety.
  • the amplification mix may contain already one or more hybridization probes which are labeled with at least one fluorescent moiety.
  • molecular beacons, FRET hybridization probes and single labeled probes are particularly useful.
  • Molecular Beacon hybridization probes are labeled with a first component and with a quencher, the labels preferably being located at both ends of the probe.
  • both components are in spatial vicinity in solution.
  • After hybridization to the target nucleic acids both components are separated from one another such that after excitation with light of a suitable wavelength the fluorescence emission of the first component can be measured (U.S. Pat. No. 5,118,801).
  • the FRET Hybridization Probe test format is especially useful for all kinds of homogenous hybridization assays (Matthews, J., A., Kricka, L., J., Analytical Biochemistry 169 (1988) 1-25). It is characterized by two single-stranded hybridization probes which are used simultaneously and are complementary to adjacent sites of the same strand of the amplified target nucleic acid. Both probes are labeled with different fluorescent components. When excited with light of a suitable wavelength, a first component transfers the absorbed energy to the second component according to the principle of fluorescence resonance energy transfer such that a fluorescence emission of the second component can be measured when both hybridization probes bind to adjacent positions of the target molecule to be detected. Alternatively to monitoring the increase in fluorescence of the FRET acceptor component, it is also possible to monitor fluorescence decrease of the FRET donor component as a quantitative measurement of hybridization event.
  • the single labeled probe consists of a single oligonucleotide labeled with a single fluorescent dye at either the 5′- or 3′-end (WO 02/14555).
  • Two different designs can be used: G-Quenching Probes and Nitroindole-Dequenching probes.
  • the fluorescent dye is attached to a C at oligo 5% or 3′-end. Fluorescence decreases significantly when the probe is hybridized to the target, in case two G's are located on the target strand opposite to C and in position 1 aside of complementary oligonucleotide probe.
  • the fluorescent dye is attached to Nitroindole at the 5′- or 3′-end of the oligonucleotide. Nitroindole somehow decreases the fluorescent signaling of the free probe. Fluorescence increases when the probe is hybridized to the target DNA due to a dequenching effect.
  • hybridization probes disclosed above are used for melting curve analysis.
  • the target nucleic acid is amplified first in a typical PCR reaction with suitable amplification primers.
  • the hybridization probes may already be present during the amplification reaction or added subsequently.
  • the temperature of the sample is constitutively increased, and fluorescence is detected as long as the hybridization probe was bound to the target DNA.
  • the hybridization probes are released from their target, and the fluorescent signal is decreasing immediately down to the background level. This decrease is monitored with an appropriate fluorescence versus temperature-time plot such that a first derivative value can be determined, at which the maximum of fluorescence decrease is observed.
  • the present invention provides a bead or a plurality of beads comprising at least two sequence specific amplification primers wherein at least one primer is bound to said support with a cleavable linker, and said primer further comprises a detectable tag.
  • the present invention also provides a library of beads, wherein each bead comprises a different pair of two sequence specific amplification primers wherein at least one primer is bound to said support with a cleavable linker, and said primer further comprises a detectable tag.
  • the bead is the tag by itself or is modified on the surface with measurable tags.
  • beads carrying specific primer sequences are encoded with any kind of detectable tag that allows the specific detection of the beads.
  • the detectable tag can be a mass-tag, a fluorescence or color label or an e-tag or a Raman tag, but is not limited to this.
  • Further examples are haptens like digoxigenin or biotin or small peptides, all of which are detectable by an antibody.
  • Another tag or a specific number of a plurality of tags can be chosen that codes either by different color, different mass or others for the bead bound specific sequence. Depending on the number of different available labels, multiple target sequences can be analyzed.
  • the primer which is bound to the bead via a cleavable linker carries a detectable tag.
  • the tag After cleaving and elongating the “cleavable”-primer the tag is incorporated into the PCR product on the beads and can be detected. Beads containing amplified product of different sequences can be differentiated and can be counted, thus enabling the possibility to qualitatively and quantitatively detect specific sequences.
  • each member of the plurality of primers which are bound to the bead via a cleavable linker carries a different detectable tag or plurality of tags.
  • the cleavable primer with a fluorescence tag this can be done in a way that the label is quenched as long as it is not elongated by polymerase to form a PCR amplicon.
  • One envisaged quenching mechanism is using primers similar to single labeled hybridization probes wherein a dequenching occurs upon interaction with the a complementary target strand.
  • primers could be used which are similar to molecular beacons, wherein a dequenching occurs upon linearization of oligonucleotide.
  • quenched primers minimizes the possibility of any background fluorescence signaling.
  • the amplification product can be detected by chemiluminescence reaction using avidin or anti-dig in a respective subsequent chemiluminescence reaction.
  • each member of the plurality of primers which are bound to the bead with a cleavable linker carries a different number of biotin or dig labels that can be detected in a reaction cascade by fluorescence or chemiluminescence Therefore a POD streptavidin and an ⁇ P anti-dig conjugate in combination with fluorogenic or chemiluminogenic substrates with different emission characteristics are used.
  • fluorescence an examplary examples is the use of fluorescene and an anti-fluorescein-galactose conjugate.
  • the time dependence or signal strength of the fluorescence or chemiluminescence signal and the emission wavelength can also additionally be used for decoding.
  • the cleavable primer and/or the noncleavable primer are modified with varying numbers Iso-G and Iso-C (which are orthogonal to standard base pairs). Biotin- and/or Dig labeled iso-G and iso-C are then incorporated during the amplification reaction and are finally detected by a reaction cascade as mentioned above.
  • Orthogonal flaps which are capable for specific interaction with a counterpart but could not interact with DNA or RNA attached to the 5′ end of the primers could also be used for “decoding by hybridization” on an array where the counterparts of the flaps are immobilized on a specific known position. Suitable orthogonal flaps are nucleic acid analogs like isoG iso C containing oligonucleotides, L-DNA, GNA and homoDNA.
  • encoded beads can also be used in combination with the detection modes of using either fluorescent entities like dsDNA binding dyes or fluorescent hybridization probes as disclosed above.
  • step c) In case clonal isolation of step c) has been achieved by means of distribution of said plurality of heads into the cavities of a micro- or picotiter plate, the PCR reaction of step can already be monitored in real time during step e) as disclosed above using an appropriate detection format. In other words, steps e) and f) are performed simultaneously by means of performing Real Time PCR analysis.
  • a micro device such as a picotiter plate (PTP) is used for physically separating different beads each carrying two PCR primers both specific for one gene.
  • PTP picotiter plate
  • One of the primers immobilized on the beads contains a cleavable linker.
  • PCR reagents are added to the beads physically separated on the PTP.
  • the beads are then exposed to cleavage conditions to cut the linker attaching the cleavable primer to the support matrix.
  • the reaction mixture is exposed to PCR cycling.
  • the still immobilized (non-cleavable) primer hybridizes to amplified molecules in close proximity—holding them at the surface.
  • PCR is performed within the single wells of the PTP and been followed in real time.
  • the amplicons may subsequently be subjected to a thermal gradient in order to perform a melting curve analysis.
  • any kind of detection format which is known in the art of real time PCR.
  • a single-stranded Hybridization Probe is labeled with two components.
  • the first component is excited with light of a suitable wavelength, the absorbed energy is transferred to the second component, the so-called quencher, according to the principle of fluorescence resonance energy transfer.
  • the hybridization probe hinds to the target DNA and is degraded by the 5′-3′ exonuclease activity of the Taq Polymerase during the subsequent elongation phase.
  • the present invention further provides for a library made by the methods of the invention.
  • the library may be made by using, e.g., genomic DNA, total cellular cDNA, a genomic DNA library, a cDNA library, or a plasmid library as the starting material for amplification.
  • the library may be derived from any population of nucleic acids, e.g., biological or synthetic in origin.
  • the present invention is also directed to a method for the amplification of multiple nucleic acid molecules of interest comprising in the steps of
  • step f) comprises in the beginning the step of distributing said plurality of beads into the cavities of a micro- or picotiter plate.
  • step c) comprises the step of distributing said plurality of beads into the cavities of a micro- or picotiter plate, the amplification products may be stored directly within the same micro- or picotiter plate.
  • the beads In case previously prepared libraries are amplified according to the invention, then it is possible to use one type of bead with one specific pair of amplification primers. In case genomic DNA or total cellular cDNA is amplified according to the invention, the beads must comprise a population of randomized forward and reverse primer sequences.
  • the present invention is also directed to a library prepared by the methods disclosed above.
  • sequencing analysis according to the present invention can be used for a variety of different applications.
  • the emPCR itself is performed with multiple beads of the same type, characterized in that all beads are carrying the same pair of amplification primers.
  • the sequencing analysis according to the present invention may be used for quantitative mutational analysis.
  • the data obtained from the plurality of different sequencing reactions reveal a plurality of different variations which occur in the target nucleic acid from a sample that has been amplified.
  • the obtained data provide quantitative information, on the percentage, how frequently each sequence variation was originally present in the analyzed sample.
  • Such an analysis can also be done in a multiplex approach.
  • the sequence variations of several different target nucleic acids which are present in a sample are determined.
  • the number of different targets that can be analyzed by this method is only limited by the number of different beads that can be provided in such a way that each bead carries a specific pair of amplification primers.
  • each bead carries a specific pair of amplification primers designed to amplify a particular region of the target DNA that shall become analyzed.
  • the design of the primers must be done in such a way that the sizes of the generated amplification products do not exceed a length, which cannot become completely sequenced in the subsequent sequencing step.
  • the generated amplicon sizes are below 1000 and most preferably below 500 nucleotides.
  • the sequences of the generated amplicons comprise overlaps between each other so that the finally generated sequence information comprises a high degree of confidence without any gaps.
  • such an analysis is useful in order to analyze multiple polymorphisms found in particular genes or gene loci, which have been proven to be associated with a predisposition of a certain disease or for the prognosis of a disease.
  • the inventive method can be used to analyze human genes such as the gene encoding muscular dystrophy or the HNPCC genes.
  • the sequencing analysis according to the present invention may be used for monitoring gene expression.
  • cDNA is used which has been prepared in such a way that the 5′ end has a target sequence which is capable of acting as a primer binding side for the subsequent amplification reaction.
  • an oligo-dT primer may be used as a second primer within said amplification reaction.
  • Introduction of the primer binding side at the 5′ end of the cDNA may be performed by any method known in the art.
  • a primer comprising a 5′ part and a 3′ part.
  • the 5′ part comprises the primer binding side which by itself does not hybridize to the first strand cDNA.
  • the 3′ part comprises an at least partially and preferably completely randomized sequence such that is capable of hybridizing to substantially all first strand cDNA molecules.
  • first strand and second cDNA synthesis are performed with a population comprising a limited number of primer sequences.
  • first strand cDNA synthesis a composition of primers is used which share a first common 5′ part corresponding to a first amplification primer binding side, but corresponding to the different number of targets that shall be monitored all have different 3′ parts.
  • second strand cDNA synthesis a composition of primers is used which share a second common 5′ part corresponding to a first amplification primer binding side, but corresponding to the different number of targets that shall be monitored all have different 3′ ends.
  • the data obtained by subsequent sequencing also reveal quantitative information on how often which cDNAs are represented within the original sample.
  • the pair of sequence specific amplification primers may be replaced by a population of completely randomized primers. If this is the case, the method according to the present invention may also be used to sequence a population of nucleic acid molecules with many different sequences such as a sample of genomic DNA or a sample of total cDNA.
  • PCR embodiments according to the present invention can be used for absolute or relative nucleic acid quantification.
  • At least two pairs of sequence specific amplification primers are used in order to amplify two different nucleic acid sequences which are present in a sample.
  • the photo cleavable primers preferably comprise different tags for subsequent detection, i.e.
  • Each member of the plurality of primers which are bound to the bead via a cleavable linker carries a different detectable label.
  • the amplification products are discriminated by means of melting curve analysis, by means of using differentially labeled hybridization probes or by means using Digoxygenin or Biotin encoded primers.
  • the sample may be for example a genomic DNA sample, a cDNA sample or an RNA sample. In the latter case, a one-step RT-PCR has to perform.
  • the sample is spiked with a known amount of standard nucleic acid, which may be amplified with primers as disclosed above and detected by means of either appropriately tagged primers or appropriately labeled probes.
  • the abundance of positive signals for each type of amplified target sequence is determined and compared to each other in order to obtain relative or (—in case of usage of a known standard—) absolute quantification data.
  • the present ends point PCR as well as real time PCR methods may be used for mutational analysis according the protocols based on the allele specific amplification, which is also called ARMS technology (U.S. Pat. No. 5,137,806, U.S. Pat. No. 5,595,890, U.S. Pat. No. 5,639,611).
  • primers with 3′ discriminating nucleotide residue are use, which are capable of amplifying only one particular sequence variation of a particular target sequence, but do not amplify a second known sequence variation.
  • Oligonucleotide synthesis was carried out on a 4 times 1 ⁇ mol scale on an ABI 394 synthesizer.
  • Commercially available tac CPG Proligo
  • All other chemicals for the standard synthesis were obtained from Glen Research.
  • Phosphoramidites with tert. butylphenoxy-acetyl protective groups (known as “tac” or “Expedite” monomers) from Proligo were used.
  • tac2O tertbutylphenoxyacetyl acetic anhydride
  • the standard protocol was used for the synthesis.
  • the product was cleaved from the support for 2 h at room temperature with 33% ammonia and purified by reversed phase chromatography on a Porous Oligo R3 4.6 ⁇ 50 mm column. Chromatography: buffer A: 0.1 M triethylammonium acetate in water pH 6.8, buffer B: 0.1 M triethylammonium acetate in water/acetonitrile 1:1, gradient 2 min 0% B to 100% B in 45 min. The UV absorption of the eluant was measured at 260 nm. A main fraction was obtained which contained the aminomodified oligonucleotide. The solvent was removed on a vacuum centrifuge.
  • the following table shows sequences and modifications of oligonucleotide primer immobilized to N-hydroxysuccinimide ester (NHS)-activated Sepharose beads.
  • Capital letters represent generic adaptor sequences for bead encoding, amplification, enrichment and pyrosequencing, whilst lower case letters represent gene specific sequences.
  • Amino-modified oligonucleotides containing stationary and photo-cleavable linker were conjugated to N-hydroxysuccinimide ester (NHS) functionalized sepharose beads (Roche/454-Life Sciences, Branford, Conn., USA) according to the standard protocol.
  • NHS N-hydroxysuccinimide ester
  • This example describes the detection of the photocleavage of fluorescein-modified oligonucleotide probes immobilized to sepharose beads.
  • the same amount of beads was suspended in 190 ⁇ l PCR-reaction mixture that was in turn emulsified according to manufacturer's instructions (OS emPCR kit User's Manual, Roche/454-Life Sciences, Branford, Conn., USA). Suspended or emulsified beads were irradiated for 15 min as described in example 2. Thereafter beads were extensively washed with isopropanol and 50 mM Tris/HCl pH 7.5 buffer. Photo-cleavage was analyzed by measuring the fluorescence intensity of beads before and after irradiation using a standard flow cytometer ( FIG. 3B ). As it can be deduced from the figure, photocleavage by means of UV irradiation in both cases resulted in a significant loss of fluorescence intensity of the bead population.
  • Template for bead PCR and a standard control PCR was an artificial 239 by amplicon.
  • the amplicon was designed in such a way that it contains a Mva I and a Nla III restriction site. Restriction endonuclease treatment of this amplicon after bead PCR or the control PCR is expected to result in characteristic patterns of different length fragments as predicted in FIG. 4 .
  • oligonucleotide probes (sequence-ID #2, #3) were suspended in 100 ⁇ l PCR-reaction mixture (Table 3) containing 1 pg of an artificial 239 by amplicon.
  • the amplicon included a sequence that was complementary to the oligonucleotides on the beads.
  • the suspension was irradiated for 15 min as described in example 2. Thereafter the suspension was transferred into PCR reaction chambers (i.e. PCR tubes). PCR was performed in a standard thermocycler as follows:
  • the beads carrying the amplified material were removed, washed in 50 mM Tris/HCl pH 7.5 buffer and subjected to restriction endonuclease treatment (ca. 5 U) for 2 h at 37° C. Subsequently beads were centrifuged and the supernatant was analyzed for specific PCR products by agarose gel electrophoresis ( FIG. 5 right side).
  • a control PCR reaction was performed using non-immobilized oligonucleotide probes ( FIG. 5 , left side). As can be seen in FIG. 5 , the bead PCR resulted in the expected large and small DNA fragments, indicating that photo-cleavage and bead PCR reaction have both worked successfully.
  • This example describes the detection of specific PCR products using bead emulsion PCR and photocleavable bead immobilized primer.
  • the beads were emulsified according to manufacturer's instructions (GS emPCR kit User's Manual, Roche/454-Life Sciences, Branford, Conn., USA).
  • the emulsion was irradiated for 30 min as described in example 2. Thereafter the emulsion was transferred into PCR reaction chambers (i.e. PCR tubes). PCR was performed in a standard thermocycler as follows:
  • the emulsified beads were recovered by a series of wash and centrifugations steps using first an excess of isopropanol, second an excess of ethanol buffer (10 mM Tris/HCl pH 7.5, 70% ethanol) and third 50 mM Tris/HCl pH 7.5 buffer.
  • the washed heads were then subjected to restriction endonuclease treatment (ca. 5 U) for 2 h at 37° C.
  • restriction endonuclease treatment ca. 5 U
  • beads were centrifuged and the supernatant was analyzed for specific PCR products by agarose gel electrophoresis.
  • As control a PCR reaction was performed using non-immobilized oligonucleotide probes.
  • FIG. 6 the bead emulsion PCR and subsequent restriction endonuclease treatment resulted in the generation of the expected DNA fragment, indicating that photo-cleavage and subsequent emPCR reaction have both worked successfully.
  • This example describes the detection of specific PCR products from human cDNA using bead emulsion PCR and photocleavable bead immobilized primer.
  • the cDNA was incubated with the beads using the hybridization procedure of Example 5. Subsequently the beads were emulsified, irradiated and subjected to amplification by PCR as outlined in Example 5.
  • the emulsified beads were recovered as described in Example 5. The washed beads were then subjected to restriction endonuclease treatment and analyzed for specific PCR products by agarose gel electrophoresis. As control photo-activated bead emulsion-PCR was performed using 2.4 pg of a 147 by amplicon of the Beta-2 microglobulin gene as template. The expected DNA fragment as shown in FIG. 7 indicates that photo-cleavage and subsequent emPCR reaction have both worked successfully with human cDNA as template. Similar results have been obtained using HeLa cDNA and beads carrying stationary and photo-cleavable oligonucleotide probes specific for the prophobilinogen deaminase gene (sequence ID #10, #11).
  • This example describes the simultaneous detection of multiple, specific PCR products using photo-activated bead PCR in suspension ( FIG. 8 ).
  • a set of distinct beads (0.2 ⁇ 106 beads each) covalently attached to stationary and photo-cleavable oligonucleotide probes specific for the genes aminolaevulinate synthase, beta-2 microglobulin and hypoxanthine-guanine phosphoribosyltransferase was suspended in 100 ⁇ l PCR-reaction mixture (Table 3). This suspension was supplemented with amplicons (ca. 0.5 pg each) of the genes aminolaevulinate synthase (127 bp), beta-2 microglobulin (174 bp) and hypoxanthine-guanine phosphoribosyltransferase (181 bp). The suspension was irradiated and subjected to amplification by PCR as outlined in example 4.
  • the beads were washed and subjected to restriction endonuclease treatment as described in example 4. After centrifugation of the beads the supernatant was analyzed for specific PCR products using a microfluidic, chromatographic chip (2100 Bioanlyzer, Agilent Technologies, Santa Clara, Calif., USA).
  • Results are shown in FIG. 9 a. Clearly, 3 different peaks were obtained, which represent fragment sizes that correspond to the fragment sizes which are theoretically expected for 127 bp, 174 bp and 181 bp amplicons.
  • This example describes the simultaneous detection of multiple, specific PCR products using photo-activated bead PCR in emulsion ( FIG. 8 ).
  • the Capture buffer contained amplicons (ca.
  • the DNA was hybridized to the beads according to the procedure of example 5. Subsequently the beads were emulsified, irradiated and subjected to amplification by PCR as outlined in example 5. After completion of the PCR reaction, the emulsified beads were recovered as described in example 5. The washed beads were then subjected to restriction endonuclease treatment (ca. 5 U) for 2 h at 37° C. After centrifugation of the beads the supernatant was analyzed for specific PCR products ( FIG. 9B ) using a microfluidic, chromatographic chip (2100 Bioanlyzer, Agilent Technologies, Santa Clara, Calif., USA).
  • Results are shown in FIG. 9 b. Again, 3 different peaks were obtained, which represent fragment sizes that correspond to the fragment sizes which are theoretically expected for 127 bp, 174 bp and 181 bp amplicons. Thus the results clearly demonstrate that the present invention is highly valuable for multiplex applications in solution as well as in the form of emulsion PCR.
  • the amplicon was annealed to the beads, emulsified, irradiated and amplified by PCR using the procedure in example 5. After completion of the PCR reaction, the emulsified beads were recovered as described in example 5. The DNA on the washed beads was rendered single stranded and sequencing primer was annealed according to manufacturer's instructions (CS emPCR kit User's Manual, Roche/454-Life Sciences, Branford, Conn., USA). Next, 250 000 beads were sequenced simultaneously by pyrophosphate sequencing using the Genome Sequencer FLX from Roche/454-Life Sciences (Branford, Conn., USA). Data processing using the software GS Amplicon Variant Analyzer confirmed the exclusive detection of the indicated amplicon.
  • each bead type was covalently attached to stationary and photo-cleavable oligonucleotide probes specific for the genes aminolaevulinate synthase, beta-2 microglobulin and hypoxanthine-guanine phosphoribosyltransferase (sequence ID #4, #5, #6, #7, #8, #9).
  • oligonucleotide probes specific for the genes aminolaevulinate synthase, beta-2 microglobulin and hypoxanthine-guanine phosphoribosyltransferase (sequence ID #4, #5, #6, #7, #8, #9).
  • 0.6 ⁇ 10 6 beads at 0.2 ⁇ 10 6 beads for each bead type were mixed with amplicons (ca.
  • the DNA on the washed beads was rendered single stranded and sequencing primer was annealed according to manufacturer's instructions (GS emPCR kit User's Manual, Roche/454-Life Sciences, Branford, Conn., USA).
  • 250 000 beads were sequenced simultaneously by pyrophosphate sequencing using the Genome Sequencer FLX from Roche/454-Life Sciences (Branford, Conn., USA).
  • Data processing using the software GS Amplicon Variant Analyzer confirmed the simultaneous detection of a mixture of different amplicons.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
US12/709,782 2009-02-25 2010-02-22 Miniaturized, high-throughput nucleic acid analysis Abandoned US20100248237A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/746,812 US8822158B2 (en) 2009-02-25 2013-01-22 Miniaturized, high-throughput nucleic acid analysis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09002627 2009-02-25
EP09002627.9 2009-02-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/746,812 Continuation US8822158B2 (en) 2009-02-25 2013-01-22 Miniaturized, high-throughput nucleic acid analysis

Publications (1)

Publication Number Publication Date
US20100248237A1 true US20100248237A1 (en) 2010-09-30

Family

ID=40552066

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/709,782 Abandoned US20100248237A1 (en) 2009-02-25 2010-02-22 Miniaturized, high-throughput nucleic acid analysis
US13/746,812 Active US8822158B2 (en) 2009-02-25 2013-01-22 Miniaturized, high-throughput nucleic acid analysis

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/746,812 Active US8822158B2 (en) 2009-02-25 2013-01-22 Miniaturized, high-throughput nucleic acid analysis

Country Status (6)

Country Link
US (2) US20100248237A1 (ja)
EP (1) EP2224014B1 (ja)
JP (1) JP5457222B2 (ja)
CN (1) CN101845494B (ja)
CA (1) CA2694745C (ja)
ES (1) ES2430853T3 (ja)

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9222115B2 (en) 2011-12-30 2015-12-29 Abbott Molecular, Inc. Channels with cross-sectional thermal gradients
US20160304860A1 (en) * 2013-02-08 2016-10-20 10X Genomics, Inc. Polynucleotide barcode generation
US9856530B2 (en) 2012-12-14 2018-01-02 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10053723B2 (en) 2012-08-14 2018-08-21 10X Genomics, Inc. Capsule array devices and methods of use
US10071377B2 (en) 2014-04-10 2018-09-11 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US10221436B2 (en) 2015-01-12 2019-03-05 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US10221442B2 (en) * 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
US10227648B2 (en) 2012-12-14 2019-03-12 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10287623B2 (en) 2014-10-29 2019-05-14 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequencing
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10400235B2 (en) 2017-05-26 2019-09-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10400280B2 (en) 2012-08-14 2019-09-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10428326B2 (en) 2017-01-30 2019-10-01 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10596541B2 (en) 2014-04-21 2020-03-24 President And Fellows Of Harvard College Systems and methods for barcoding nucleic acids
US10669575B2 (en) 2011-10-14 2020-06-02 Becton, Dickinson And Company Square wave thermal cycling
US10697000B2 (en) 2015-02-24 2020-06-30 10X Genomics, Inc. Partition processing methods and systems
US10745742B2 (en) 2017-11-15 2020-08-18 10X Genomics, Inc. Functionalized gel beads
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10774370B2 (en) 2015-12-04 2020-09-15 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
US10947587B2 (en) * 2013-11-05 2021-03-16 The Regents Of The University Of California Single-cell forensic short tandem repeat typing within microfluidic droplets
US11001883B2 (en) 2012-03-05 2021-05-11 The General Hospital Corporation Systems and methods for epigenetic sequencing
US11084036B2 (en) 2016-05-13 2021-08-10 10X Genomics, Inc. Microfluidic systems and methods of use
US11135584B2 (en) 2014-11-05 2021-10-05 10X Genomics, Inc. Instrument systems for integrated sample processing
US11155881B2 (en) 2018-04-06 2021-10-26 10X Genomics, Inc. Systems and methods for quality control in single cell processing
US11203787B2 (en) 2012-08-13 2021-12-21 The Regents Of The University Of California Methods and systems for detecting biological components
US11274343B2 (en) 2015-02-24 2022-03-15 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequence coverage
US11312990B2 (en) * 2014-06-27 2022-04-26 The Regents Of The University Of California PCR-activated sorting (PAS)
US11351510B2 (en) 2006-05-11 2022-06-07 Bio-Rad Laboratories, Inc. Microfluidic devices
US11511242B2 (en) 2008-07-18 2022-11-29 Bio-Rad Laboratories, Inc. Droplet libraries
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US11629344B2 (en) 2014-06-26 2023-04-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
AU2020244615B2 (en) * 2013-06-27 2023-06-08 10X Genomics, Inc. Compositions and methods for sample processing
US11680292B2 (en) 2018-06-29 2023-06-20 Illumina, Inc. Flow cells
US11732287B2 (en) 2015-02-04 2023-08-22 The Regents Of The University Of California Sequencing of nucleic acids via barcoding in discrete entities
US11747327B2 (en) 2011-02-18 2023-09-05 Bio-Rad Laboratories, Inc. Compositions and methods for molecular labeling
US11746367B2 (en) 2015-04-17 2023-09-05 President And Fellows Of Harvard College Barcoding systems and methods for gene sequencing and other applications
US11773389B2 (en) 2017-05-26 2023-10-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US11781129B2 (en) 2017-10-18 2023-10-10 Mission Bio, Inc. Method, systems and apparatus for single cell analysis
US11819849B2 (en) 2007-02-06 2023-11-21 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US11898193B2 (en) 2011-07-20 2024-02-13 Bio-Rad Laboratories, Inc. Manipulating droplet size
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
US12091710B2 (en) 2006-05-11 2024-09-17 Bio-Rad Laboratories, Inc. Systems and methods for handling microfluidic droplets

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5954876B2 (ja) 2009-10-13 2016-07-20 ナノストリング テクノロジーズ， インコーポレイテッド ナノレポーターによるタンパク質の検出
US9650629B2 (en) 2010-07-07 2017-05-16 Roche Molecular Systems, Inc. Clonal pre-amplification in emulsion
US9476095B2 (en) 2011-04-15 2016-10-25 The Johns Hopkins University Safe sequencing system
KR102078892B1 (ko) 2012-02-09 2020-02-19 라이프 테크놀로지스 코포레이션 접합된 중합체성 입자 및 그의 제조 방법
GB201212775D0 (en) 2012-07-18 2012-08-29 Dna Electronics Ltd Sensing apparatus and method
EP3447495B2 (en) 2012-10-29 2024-03-13 The Johns Hopkins University Papanicolaou test for ovarian and endometrial cancers
EP3126512B1 (en) * 2014-02-26 2019-04-17 Ventana Medical Systems, Inc. Photo-selective method for biological sample analysis field
JP6853667B2 (ja) * 2014-04-21 2021-03-31 プレジデント アンド フェローズ オブ ハーバード カレッジ 核酸をバーコーディングするためのシステムおよび方法
CN114507715A (zh) * 2014-11-20 2022-05-17 安普里怀斯公司 用于核酸扩增的组合物和方法
WO2016151719A1 (ja) * 2015-03-23 2016-09-29 株式会社日立製作所 核酸反応デバイス
CN107922974B (zh) 2015-07-02 2021-11-09 生命技术公司 羧基官能亲水微珠的偶合
US10150992B2 (en) * 2015-07-06 2018-12-11 Life Technologies Corporation Substrates and methods useful in sequencing
WO2017027653A1 (en) 2015-08-11 2017-02-16 The Johns Hopkins University Assaying ovarian cyst fluid
CN105297143A (zh) * 2015-09-22 2016-02-03 江苏大学 基于乳液不对称PCR的ssDNA次级文库的制备方法
JP2017209048A (ja) * 2016-05-25 2017-11-30 株式会社ニコン 標的生体分子の濃度算出方法、標的生体分子濃度算出用ビーズ、ビーズのセット、及び標的生体分子濃度算出装置
JPWO2017204294A1 (ja) 2016-05-25 2019-02-21 株式会社ニコン 標的生体分子の特定方法、標的生体分子特定用ビーズ、ビーズのセット、及び標的生体分子特定装置
JP2017209051A (ja) * 2016-05-25 2017-11-30 株式会社ニコン 標的生体分子の検出方法、標的生体分子検出用基板、及び標的生体分子検出装置
JP2017209049A (ja) * 2016-05-25 2017-11-30 株式会社ニコン 標的生体分子の特定方法、標的生体分子特定用ビーズ、ビーズのセット、及び標的生体分子特定装置
CA3072195A1 (en) 2017-08-07 2019-04-04 The Johns Hopkins University Methods and materials for assessing and treating cancer
MX2021003772A (es) * 2018-10-26 2021-05-27 Illumina Inc Modulacion de globulos de polimero para procesamiento de adn.
EP3957733A4 (en) * 2019-04-19 2023-05-24 Nihon University SIMPLE PROCEDURE FOR DETECTING NUCLEIC ACID SEQUENCES ETC.
EP4200414A4 (en) * 2020-08-21 2024-10-09 Ultima Genomics Inc SURFACE AMPLIFICATION COMPOSITIONS AND USES THEREOF
CN113262730B (zh) * 2021-03-29 2022-11-22 上海迪赢生物科技有限公司 一种基于簇式阵列的高通量自动化基因合成装置

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118801A (en) * 1988-09-30 1992-06-02 The Public Health Research Institute Nucleic acid process containing improved molecular switch
US5137806A (en) * 1989-12-11 1992-08-11 Board Of Regents, The University Of Texas System Methods and compositions for the detection of sequences in selected DNA molecules
US5258506A (en) * 1984-10-16 1993-11-02 Chiron Corporation Photolabile reagents for incorporation into oligonucleotide chains
US5496699A (en) * 1992-04-27 1996-03-05 Trustees Of Darmouth College Detection of allele - specific mutagens
US5521301A (en) * 1988-12-12 1996-05-28 City Of Hope Genotyping of multiple allele systems
US5595890A (en) * 1988-03-10 1997-01-21 Zeneca Limited Method of detecting nucleotide sequences
US5639603A (en) * 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
US5639611A (en) * 1988-12-12 1997-06-17 City Of Hope Allele specific polymerase chain reaction
US5641658A (en) * 1994-08-03 1997-06-24 Mosaic Technologies, Inc. Method for performing amplification of nucleic acid with two primers bound to a single solid support
US5677152A (en) * 1995-08-25 1997-10-14 Roche Molecular Systems, Inc. Nucleic acid amplification using a reersibly inactivated thermostable enzyme
US5693502A (en) * 1990-06-11 1997-12-02 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US5792607A (en) * 1990-01-26 1998-08-11 Abbott Laboratories Method and kits for amplifying target nucleic acids applicable to both polymerase and ligase chain reactions
US5804375A (en) * 1990-08-06 1998-09-08 Roche Molecular Systems, Inc. Reaction mixtures for detection of target nucleic acids
US5871908A (en) * 1992-02-05 1999-02-16 Evotec Biosystems Gmbh Process for the determination of in vitro amplified nucleic acids
US6090592A (en) * 1994-08-03 2000-07-18 Mosaic Technologies, Inc. Method for performing amplification of nucleic acid on supports
US6174670B1 (en) * 1996-06-04 2001-01-16 University Of Utah Research Foundation Monitoring amplification of DNA during PCR
US6210891B1 (en) * 1996-09-27 2001-04-03 Pyrosequencing Ab Method of sequencing DNA
US20070087362A1 (en) * 2004-02-27 2007-04-19 President And Fellows Of Harvard College Polony fluorescent in situ sequencing beads
US20100143908A1 (en) * 2006-11-15 2010-06-10 Biospherex, Llc, A Limited Liability Company Multitag sequencing ecogenomics analysis-us
US20100248991A1 (en) * 2009-02-25 2010-09-30 Angelika Roesler Solid support for high-throughput nucleic acid analysis
US8048627B2 (en) * 2003-07-05 2011-11-01 The Johns Hopkins University Method and compositions for detection and enumeration of genetic variations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US6033851A (en) 1994-12-09 2000-03-07 Wakunaga Seiyaku Kabushiki Kaisha Method for suppressing nonspecific hybridization in primer extension method
CA2176193A1 (en) 1995-05-22 1996-11-23 John Wesley Backus Methods for polymerase chain reaction preamplification sterilization by exonucleases in the presence of phosphorothioated primers
WO1998020019A1 (en) 1996-11-06 1998-05-14 Sequenom, Inc. Compositions and methods for immobilizing nucleic acids to solid supports
EP1054726B1 (en) 1998-02-11 2003-07-30 University of Houston, Office of Technology Transfer Apparatus for chemical and biochemical reactions using photo-generated reagents
CA2382157C (en) 1999-08-18 2012-04-03 Illumina, Inc. Compositions and methods for preparing oligonucleotide solutions
AU2001241723A1 (en) 2000-02-25 2001-09-03 Affymetrix, Inc. Methods for multi-stage solid phase amplification of nucleic acids
WO2002014555A2 (en) 2000-08-11 2002-02-21 University Of Utah Research Foundation Single-labeled oligonucleotide probes
EP1275735A1 (en) 2001-07-11 2003-01-15 Roche Diagnostics GmbH Composition and method for hot start nucleic acid amplification
US7582429B2 (en) 2002-10-23 2009-09-01 University Of Utah Research Foundation Amplicon melting analysis with saturation dyes
DE602004036672C5 (de) 2003-01-29 2012-11-29 454 Life Sciences Corporation Nukleinsäureamplifikation auf Basis von Kügelchenemulsion
WO2006117556A2 (en) 2005-05-04 2006-11-09 The Institute Of Cancer Research: Royal Cancer Hospital Materials and methods for the photodirected synthesis of oligonucleotide arrays
KR100828714B1 (ko) * 2005-10-25 2008-05-09 주식회사 엘지화학 리보핵산을 이용한 멀티플렉스 증폭방법
GB0601031D0 (en) 2006-01-18 2006-03-01 Novartis Ag Organic compounds
WO2007111937A1 (en) * 2006-03-23 2007-10-04 Applera Corporation Directed enrichment of genomic dna for high-throughput sequencing
WO2007136736A2 (en) 2006-05-19 2007-11-29 Codon Devices, Inc. Methods for nucleic acid sorting and synthesis
US8083633B2 (en) 2009-03-27 2011-12-27 GM Global Technology Operations LLC 8-speed hybrid transmission

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258506A (en) * 1984-10-16 1993-11-02 Chiron Corporation Photolabile reagents for incorporation into oligonucleotide chains
US5595890A (en) * 1988-03-10 1997-01-21 Zeneca Limited Method of detecting nucleotide sequences
US5118801A (en) * 1988-09-30 1992-06-02 The Public Health Research Institute Nucleic acid process containing improved molecular switch
US5639611A (en) * 1988-12-12 1997-06-17 City Of Hope Allele specific polymerase chain reaction
US5521301A (en) * 1988-12-12 1996-05-28 City Of Hope Genotyping of multiple allele systems
US5137806A (en) * 1989-12-11 1992-08-11 Board Of Regents, The University Of Texas System Methods and compositions for the detection of sequences in selected DNA molecules
US5792607A (en) * 1990-01-26 1998-08-11 Abbott Laboratories Method and kits for amplifying target nucleic acids applicable to both polymerase and ligase chain reactions
US5693502A (en) * 1990-06-11 1997-12-02 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US5804375A (en) * 1990-08-06 1998-09-08 Roche Molecular Systems, Inc. Reaction mixtures for detection of target nucleic acids
US5639603A (en) * 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
US5871908A (en) * 1992-02-05 1999-02-16 Evotec Biosystems Gmbh Process for the determination of in vitro amplified nucleic acids
US5496699A (en) * 1992-04-27 1996-03-05 Trustees Of Darmouth College Detection of allele - specific mutagens
US6090592A (en) * 1994-08-03 2000-07-18 Mosaic Technologies, Inc. Method for performing amplification of nucleic acid on supports
US5641658A (en) * 1994-08-03 1997-06-24 Mosaic Technologies, Inc. Method for performing amplification of nucleic acid with two primers bound to a single solid support
US5773258A (en) * 1995-08-25 1998-06-30 Roche Molecular Systems, Inc. Nucleic acid amplification using a reversibly inactivated thermostable enzyme
US5677152A (en) * 1995-08-25 1997-10-14 Roche Molecular Systems, Inc. Nucleic acid amplification using a reersibly inactivated thermostable enzyme
US6174670B1 (en) * 1996-06-04 2001-01-16 University Of Utah Research Foundation Monitoring amplification of DNA during PCR
US6210891B1 (en) * 1996-09-27 2001-04-03 Pyrosequencing Ab Method of sequencing DNA
US8048627B2 (en) * 2003-07-05 2011-11-01 The Johns Hopkins University Method and compositions for detection and enumeration of genetic variations
US20070087362A1 (en) * 2004-02-27 2007-04-19 President And Fellows Of Harvard College Polony fluorescent in situ sequencing beads
US20100143908A1 (en) * 2006-11-15 2010-06-10 Biospherex, Llc, A Limited Liability Company Multitag sequencing ecogenomics analysis-us
US20100248991A1 (en) * 2009-02-25 2010-09-30 Angelika Roesler Solid support for high-throughput nucleic acid analysis

Cited By (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12091710B2 (en) 2006-05-11 2024-09-17 Bio-Rad Laboratories, Inc. Systems and methods for handling microfluidic droplets
US11351510B2 (en) 2006-05-11 2022-06-07 Bio-Rad Laboratories, Inc. Microfluidic devices
US11819849B2 (en) 2007-02-06 2023-11-21 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US11596908B2 (en) 2008-07-18 2023-03-07 Bio-Rad Laboratories, Inc. Droplet libraries
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
US11511242B2 (en) 2008-07-18 2022-11-29 Bio-Rad Laboratories, Inc. Droplet libraries
US11534727B2 (en) 2008-07-18 2022-12-27 Bio-Rad Laboratories, Inc. Droplet libraries
US11965877B2 (en) 2011-02-18 2024-04-23 Bio-Rad Laboratories, Inc. Compositions and methods for molecular labeling
US11768198B2 (en) 2011-02-18 2023-09-26 Bio-Rad Laboratories, Inc. Compositions and methods for molecular labeling
US11747327B2 (en) 2011-02-18 2023-09-05 Bio-Rad Laboratories, Inc. Compositions and methods for molecular labeling
US11898193B2 (en) 2011-07-20 2024-02-13 Bio-Rad Laboratories, Inc. Manipulating droplet size
US10669575B2 (en) 2011-10-14 2020-06-02 Becton, Dickinson And Company Square wave thermal cycling
US9222115B2 (en) 2011-12-30 2015-12-29 Abbott Molecular, Inc. Channels with cross-sectional thermal gradients
US10052632B2 (en) 2011-12-30 2018-08-21 Abbott Molecular Inc. Channels with cross-sectional thermal gradients
US11047003B2 (en) 2012-03-05 2021-06-29 The General Hospital Corporation Systems and methods for epigenetic sequencing
US11001883B2 (en) 2012-03-05 2021-05-11 The General Hospital Corporation Systems and methods for epigenetic sequencing
US11891666B2 (en) 2012-08-13 2024-02-06 The Regents Of The University Of California Methods and systems for detecting biological components
US11203787B2 (en) 2012-08-13 2021-12-21 The Regents Of The University Of California Methods and systems for detecting biological components
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US10450607B2 (en) 2012-08-14 2019-10-22 10X Genomics, Inc. Methods and systems for processing polynucleotides
US12098423B2 (en) 2012-08-14 2024-09-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10221442B2 (en) * 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11035002B2 (en) 2012-08-14 2021-06-15 10X Genomics, Inc. Methods and systems for processing polynucleotides
US12037634B2 (en) 2012-08-14 2024-07-16 10X Genomics, Inc. Capsule array devices and methods of use
US11021749B2 (en) 2012-08-14 2021-06-01 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11078522B2 (en) * 2012-08-14 2021-08-03 10X Genomics, Inc. Capsule array devices and methods of use
US10400280B2 (en) 2012-08-14 2019-09-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
AU2022200718B2 (en) * 2012-08-14 2024-03-14 10X Genomics, Inc. Microcapsule compositions and methods
US10669583B2 (en) 2012-08-14 2020-06-02 10X Genomics, Inc. Method and systems for processing polynucleotides
US10053723B2 (en) 2012-08-14 2018-08-21 10X Genomics, Inc. Capsule array devices and methods of use
AU2020203602B2 (en) * 2012-08-14 2022-01-27 10X Genomics, Inc. Microcapsule compositions and methods
AU2020203602C1 (en) * 2012-08-14 2022-05-05 10X Genomics, Inc. Microcapsule compositions and methods
US11359239B2 (en) 2012-08-14 2022-06-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11441179B2 (en) 2012-08-14 2022-09-13 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10584381B2 (en) 2012-08-14 2020-03-10 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10597718B2 (en) 2012-08-14 2020-03-24 10X Genomics, Inc. Methods and systems for sample processing polynucleotides
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10752950B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10626458B2 (en) 2012-08-14 2020-04-21 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10612090B2 (en) 2012-12-14 2020-04-07 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10676789B2 (en) 2012-12-14 2020-06-09 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9856530B2 (en) 2012-12-14 2018-01-02 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10227648B2 (en) 2012-12-14 2019-03-12 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11473138B2 (en) 2012-12-14 2022-10-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10253364B2 (en) 2012-12-14 2019-04-09 10X Genomics, Inc. Method and systems for processing polynucleotides
US11421274B2 (en) 2012-12-14 2022-08-23 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11193121B2 (en) 2013-02-08 2021-12-07 10X Genomics, Inc. Partitioning and processing of analytes and other species
US10150963B2 (en) 2013-02-08 2018-12-11 10X Genomics, Inc. Partitioning and processing of analytes and other species
US20160304860A1 (en) * 2013-02-08 2016-10-20 10X Genomics, Inc. Polynucleotide barcode generation
US10150964B2 (en) 2013-02-08 2018-12-11 10X Genomics, Inc. Partitioning and processing of analytes and other species
AU2020244615B2 (en) * 2013-06-27 2023-06-08 10X Genomics, Inc. Compositions and methods for sample processing
US10947587B2 (en) * 2013-11-05 2021-03-16 The Regents Of The University Of California Single-cell forensic short tandem repeat typing within microfluidic droplets
US10071377B2 (en) 2014-04-10 2018-09-11 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US12005454B2 (en) 2014-04-10 2024-06-11 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US10137449B2 (en) 2014-04-10 2018-11-27 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US10343166B2 (en) 2014-04-10 2019-07-09 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US10150117B2 (en) 2014-04-10 2018-12-11 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US10596541B2 (en) 2014-04-21 2020-03-24 President And Fellows Of Harvard College Systems and methods for barcoding nucleic acids
US11052368B2 (en) 2014-04-21 2021-07-06 Vilnius University Systems and methods for barcoding nucleic acids
US11629344B2 (en) 2014-06-26 2023-04-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10457986B2 (en) 2014-06-26 2019-10-29 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10480028B2 (en) 2014-06-26 2019-11-19 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10208343B2 (en) 2014-06-26 2019-02-19 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10337061B2 (en) 2014-06-26 2019-07-02 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10344329B2 (en) 2014-06-26 2019-07-09 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10030267B2 (en) 2014-06-26 2018-07-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10041116B2 (en) 2014-06-26 2018-08-07 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10760124B2 (en) 2014-06-26 2020-09-01 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11713457B2 (en) 2014-06-26 2023-08-01 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11312990B2 (en) * 2014-06-27 2022-04-26 The Regents Of The University Of California PCR-activated sorting (PAS)
US20230109667A2 (en) * 2014-06-27 2023-04-06 The Regents Of The University Of California PCR-Activated Sorting (PAS)
US11739368B2 (en) 2014-10-29 2023-08-29 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequencing
US10287623B2 (en) 2014-10-29 2019-05-14 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequencing
US11135584B2 (en) 2014-11-05 2021-10-05 10X Genomics, Inc. Instrument systems for integrated sample processing
US10221436B2 (en) 2015-01-12 2019-03-05 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US11414688B2 (en) 2015-01-12 2022-08-16 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US10557158B2 (en) 2015-01-12 2020-02-11 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US11732287B2 (en) 2015-02-04 2023-08-22 The Regents Of The University Of California Sequencing of nucleic acids via barcoding in discrete entities
US11603554B2 (en) 2015-02-24 2023-03-14 10X Genomics, Inc. Partition processing methods and systems
US10697000B2 (en) 2015-02-24 2020-06-30 10X Genomics, Inc. Partition processing methods and systems
US11274343B2 (en) 2015-02-24 2022-03-15 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequence coverage
US11746367B2 (en) 2015-04-17 2023-09-05 President And Fellows Of Harvard College Barcoding systems and methods for gene sequencing and other applications
US10774370B2 (en) 2015-12-04 2020-09-15 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US11473125B2 (en) 2015-12-04 2022-10-18 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US11873528B2 (en) 2015-12-04 2024-01-16 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US11624085B2 (en) 2015-12-04 2023-04-11 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US11084036B2 (en) 2016-05-13 2021-08-10 10X Genomics, Inc. Microfluidic systems and methods of use
US10793905B2 (en) 2016-12-22 2020-10-06 10X Genomics, Inc. Methods and systems for processing polynucleotides
US12084716B2 (en) 2016-12-22 2024-09-10 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11180805B2 (en) 2016-12-22 2021-11-23 10X Genomics, Inc Methods and systems for processing polynucleotides
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10858702B2 (en) 2016-12-22 2020-12-08 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10480029B2 (en) 2016-12-22 2019-11-19 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10323278B2 (en) 2016-12-22 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10428326B2 (en) 2017-01-30 2019-10-01 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
US11193122B2 (en) 2017-01-30 2021-12-07 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
US10400235B2 (en) 2017-05-26 2019-09-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US11198866B2 (en) 2017-05-26 2021-12-14 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10844372B2 (en) 2017-05-26 2020-11-24 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10927370B2 (en) 2017-05-26 2021-02-23 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US11155810B2 (en) 2017-05-26 2021-10-26 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US11773389B2 (en) 2017-05-26 2023-10-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US11781129B2 (en) 2017-10-18 2023-10-10 Mission Bio, Inc. Method, systems and apparatus for single cell analysis
US11884962B2 (en) 2017-11-15 2024-01-30 10X Genomics, Inc. Functionalized gel beads
US10876147B2 (en) 2017-11-15 2020-12-29 10X Genomics, Inc. Functionalized gel beads
US10745742B2 (en) 2017-11-15 2020-08-18 10X Genomics, Inc. Functionalized gel beads
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
US11155881B2 (en) 2018-04-06 2021-10-26 10X Genomics, Inc. Systems and methods for quality control in single cell processing
US11988957B2 (en) 2018-06-29 2024-05-21 Illumina, Inc. Flow cells
US11680292B2 (en) 2018-06-29 2023-06-20 Illumina, Inc. Flow cells

Also Published As

Publication number Publication date
CN101845494A (zh) 2010-09-29
EP2224014A1 (en) 2010-09-01
CA2694745C (en) 2015-05-05
US20130190191A1 (en) 2013-07-25
CN101845494B (zh) 2015-11-25
EP2224014B1 (en) 2013-07-17
US8822158B2 (en) 2014-09-02
JP5457222B2 (ja) 2014-04-02
CA2694745A1 (en) 2010-08-25
JP2010193884A (ja) 2010-09-09
ES2430853T3 (es) 2013-11-22

Similar Documents

Publication Publication Date Title
US8822158B2 (en) Miniaturized, high-throughput nucleic acid analysis
US9347092B2 (en) Solid support for high-throughput nucleic acid analysis
US11634768B2 (en) Methods for indexing samples and sequencing multiple polynucleotide templates
EP3615690B1 (en) Compositions and methods for improving sample identification in indexed nucleic acid libraries
JP4480715B2 (ja) 二重末端シーケンシング
US20040072200A1 (en) Detection of nucleic acid polymorphisms
US20030108900A1 (en) Multiplex nucleic acid reactions
JP2003521252A (ja) ユニバーサルプライミングを用いる核酸検出方法
JP2004512843A (ja) 核酸の増幅および任意のキャラクタリゼーションの方法
US7408051B2 (en) Modified oligonucleotides and applications thereof
JP2022533916A (ja) 自家発光に基づく単一チャネルシーケンシング法
EP2246438A1 (en) Multiplex nucleic acid reactions
US20180073063A1 (en) Reusable microarray compositions and methods
TW201723189A (zh) 用於基因型鑑定晶片之雙重等位基因特異性聚合酶鏈鎖反應的方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: ROCHE DIAGNOSTICS OPERATIONS, INC., INDIANA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ROCHE DIAGNOSTICS GMBH;REEL/FRAME:024480/0872

Effective date: 20100526

Owner name: ROCHE DIAGNOSTICS GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FROEHLICH, THOMAS;ROESLER, ANGELIKA;HEINDL, DIETER;SIGNING DATES FROM 20100511 TO 20100517;REEL/FRAME:024480/0779

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: ROCHE MOLECULAR SYSTEMS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ROCHE DIAGNOSTICS OPERATIONS, INC.;REEL/FRAME:032039/0455

Effective date: 20140115